Crizanlizumab for vaso-occlusive crisis in SCDJanuary 6, 2020
USFDA has approved crizanlizumab (Adakveo) as the first therapy to reduce the frequency of vaso-occlusive crisis, a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells, Novartis said.
The approval was based on the results of a randomized clinical trial enrolling 198 patients with sickle cell disease with a history of vaso-occlusive crisis. Patients either received crizanlizumab or a placebo.
The patients treated with crizanlizumab experienced fewer health care visits for vaso-occlusive crisis annually (median annual rate of 1.63 visits), compared to patients who received a placebo (median annual rate of 2.98 visits).
In addition, 36 percent of patients who received crizanlizumab did not experience a vaso-occlusive crisis during the study, and it delayed the time that patients first experienced vaso-occlusive crisis after starting treatment from 1.4 months to 4.1 months.